Abbott's New Leadless Pacemaker System Meets Main Goal In Pivotal Trial

Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial.

The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms.

Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. The leadless pacemaker is currently being evaluated for the FDA approval.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft Corp. (MSFT) said it plans to acquire Activision Blizzard Inc. (ATVI) for $95.00 per share, in an all-cash deal valued at $68.7 billion, inclusive of Activision Blizzard's net cash. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like Warcraft,... Goldman Sachs Group Inc. reported Tuesday that profit for the fourth quarter declined 13 percent from last year, reflecting an 8 percent drop in net revenues, higher operating expenses and higher provisions for bad loans. Earnings for the quarter missed analysts' expectations, but quarterly revenues topped it. Amazon has dropped its earlier plan to stop accepting credit cards issued by Visa Inc. in the United Kingdom. The e-commerce giant said it is working on a potential solution with the payments processor to resolve a dispute over the payment fees. In an email to customers, the company reportedly said, "The expected change regarding the use of Visa credit cards on Amazon.co.uk will no longer take...
Follow RTT